Wells Fargo analyst Peter Costa reduced his estimates for Walgreens Boots Alliance to reflect greater headwinds from reimbursement pressure, less deflation of generics, a weaker flu season, and potentially slowed tobacco-related sales. It seems increasingly likely that the company may lower its fiscal 2019 outlook, Costa tells investors in a research note. He points out that at a recent competitor conference, management did not provide an update to its earnings outlook, but highlighted reimbursement pressure as a bigger headwind as well as less deflation of generics. Costa dropped his price target for Walgreens Boots Alliance to $75 from $82 but keeps an Outperform rating on the name.